Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Compass Therapeutics (CMPX) Other Working Capital Changes (2023 - 2025)

Compass Therapeutics' Other Working Capital Changes history spans 3 years, with the latest figure at -$4.8 million for Q4 2025.

  • For Q4 2025, Other Working Capital Changes rose 13.55% year-over-year to -$4.8 million; the TTM value through Dec 2025 reached -$5.1 million, down 320.38%, while the annual FY2025 figure was -$5.1 million, 320.38% down from the prior year.
  • Other Working Capital Changes for Q4 2025 was -$4.8 million at Compass Therapeutics, down from $452000.0 in the prior quarter.
  • Across five years, Other Working Capital Changes topped out at $5.0 million in Q2 2024 and bottomed at -$5.5 million in Q4 2024.
  • The 3-year median for Other Working Capital Changes is -$995500.0 (2023), against an average of -$1.1 million.
  • The largest YoY upside for Other Working Capital Changes was 359.57% in 2024 against a maximum downside of 278.85% in 2024.
  • A 3-year view of Other Working Capital Changes shows it stood at -$1.5 million in 2023, then plummeted by 278.85% to -$5.5 million in 2024, then increased by 13.55% to -$4.8 million in 2025.
  • Per Business Quant, the three most recent readings for CMPX's Other Working Capital Changes are -$4.8 million (Q4 2025), $452000.0 (Q3 2025), and -$530000.0 (Q2 2025).